NET PROFIT (x1000 SEK)
EMPLOYEES
Chosa Oncology AB
Closing information (x1000 SEK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
0
![]() |
0
![]() |
0 |
Financial expenses |
544
|
1,476
|
220 |
Earnings before taxes |
-23,752
|
-41,112
|
-62,077 |
EBITDA |
-22,742
|
-41,116
|
-61,857 |
Total assets |
19,426
|
27,885
|
55,830 |
Current assets |
9,525
|
27,885
|
55,830 |
Current liabilities |
2,015
|
18,841
|
14,135 |
Equity capital |
17,411
|
9,044
|
41,695 |
- share capital |
11,677
|
3,428
![]() |
3,428 |
Employees (average) |
1
|
4
![]() |
4 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
89.6%
|
32.4%
|
74.7% |
Turnover per employee |
0
![]() |
0
![]() |
0 |
Profit as a percentage of turnover | |||
Return on assets (ROA) |
-119.5%
|
-142.1%
|
-110.8% |
Current ratio |
472.7%
|
148.0%
|
395.0% |
Return on equity (ROE) |
-136.4%
|
-454.6%
|
-148.9% |
Change turnover |
0
![]() |
0
![]() |
0 |
Change turnover % | |||
Chg. No. of employees |
-3
|
0
|
1 |
Chg. No. of employees % |
-75%
|
0%
|
33% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.